Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NMUR2 | Q9GZQ4 | 5/20 | 0.46 |
| ▸ | NMUR1 | Q9HB89 | 5/20 | 0.46 |
| ▸ | APLNR | P35414 | 1/20 | 0.46 |
| ▸ | PLK1 | P53350 | 1/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.42 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.42 |
| ▸ | F2 | P00734 | 2/20 | 0.42 |
| ▸ | F10 | P00742 | 2/20 | 0.42 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.42 |
| ▸ | PLG | P00747 | 1/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31072443 | 0.97 | APLNR (0.48) | NMUR2NMUR1APLNROPRM1OPRK1 | |
| SCHEMBL29800433 | 0.84 | NRP1 (0.48) | NMUR2NMUR1PLK1F2 | |
| SCHEMBL9007763 | 0.84 | CXCR4 (0.43) | NMUR2NMUR1PLK1OPRM1OPRK1 | |
| SCHEMBL29520310 | 0.84 | CXCR4 (0.43) | NMUR2NMUR1PLK1OPRM1OPRK1 | |
| SCHEMBL11438170 | 0.84 | CXCR4 (0.43) | NMUR2NMUR1PLK1OPRM1OPRK1 | |
| Hydrochloric Acid SCHEMBL7699051 | 0.83 | CXCR4 (0.42) | NMUR2NMUR1PLK1OPRM1OPRK1 | |
| SCHEMBL30307576 | 0.83 | NRP1 (0.47) | NMUR2NMUR1OPRM1OPRD1F2 | |
| SCHEMBL1373233 | 0.83 | APLNR (0.44) | NMUR2NMUR1APLNROPRM1OPRK1 | |
| SCHEMBL1373230 | 0.83 | APLNR (0.44) | NMUR2NMUR1APLNROPRM1OPRK1 | |
| SCHEMBL30979608 | 0.82 | NMUR2 (0.42) | NMUR2NMUR1APLNROPRM1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240279278-A1 | NMU RECEPTOR 2 AGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2024-08-22 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240279278-A1 | NMU RECEPTOR 2 AGONISTS | NMUR2, NMUR1, NMBR | NMUR2 1/4885NMUR1 2/4885APLNR 68/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.